Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression
Authors:
- 1 January 2018
- journal article
- research article
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 33 (1) , 34-43
Abstract
Patients with treatment-resistant unipolar depression (TRD) are treated with antidepressant combinations (ADs) or with second-generation antipsychotics plus AD (SGA+AD) augmentation; however, the clinical characteristics, the factors associated independently with response to SGA+AD, and the outcome trajectories have not yet been characterized. We performed a naturalistic study on the latest stable trial (medication unchanged for about 3 months) in 86 TRD patients with resistance to at least two ADs trials, who received ADs (n=36) or SGA+AD (n=50) treatments. Montgomery–Asberg Depression Rating Scale (MADRS), Hamilton-Depression Rating Scale (HAM-D17), and other scales were administered before (T0) and after the latest 3-month stable trial (T3). Compared to ADs, the SGA+AD group showed increased percentage of depression with psychotic features, comorbidity for personality disorders and substance use disorders (SUD), higher number of failed ADs pharmacotherapies and depressive symptoms at T0 on all scales (P<0.001). Compared to T0, both treatments significantly decreased depressive symptoms on MADRS and HAM-D17 at T3 (P<0.001); however, the SGA+AD augmentation produced a greater decline in mean score. Logistic regression analysis indicated that psychotic features, personality disorders, and SUD were independently associated with SGA+AD treatment. Given the greater improvement in depression following SGA+AD augmentation, SGA augmentation should be indicated as a first-line treatment in severe TRD with psychotic features, SUD, and personality disorders.Keywords
This publication has 58 references indexed in Scilit:
- Neurotransmitter Targeting in the Treatment of DepressionThe Journal of Clinical Psychiatry, 2013
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disordersThe World Journal of Biological Psychiatry, 2013
- Rational site-directed pharmacotherapy for major depressive disorderInternational Journal of Neuropsychopharmacology, 2013
- A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorderJournal of Affective Disorders, 2010
- Efficacy, safety and tolerability of Symbyax®for acute-phase management of treatment-resistant depressionExpert Review of Neurotherapeutics, 2010
- Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiationEuropean Neuropsychopharmacology, 2009
- Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients With Major Depressive DisorderThe Journal of Clinical Psychiatry, 2009
- Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to AntidepressantsCNS Spectrums, 2009
- The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive DisorderThe Journal of Clinical Psychiatry, 2007
- Current advances and trends in the treatment of depressionTrends in Pharmacological Sciences, 1994